Abstracts tagged "autoantigens"

Abstract Number: 630 • 2013 ACR/ARHP Annual Meeting
Galectin-3-Binding Protein Is Highly Increased On Circulating Microparticles In SLE Patients and Co-Localizes With IgG In Glomerular Deposits In Human Lupus Nephritis
Christoffer T. Nielsen^1,2, Ole Østergaard³, Ole Petter Rekvig⁴, Gunnar K. Sturfelt⁵, Søren Jacobsen⁶ and Niels H. H. Heegaard⁷, ¹Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen S, Denmark, ²Infectious Diseases and Rheumatology, University Hospital Rigshospitalet, Copenhagen, Denmark, ³Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institute, Copenhagen S, Denmark, ⁴Department of Biochemistry and Medical Biology, University Hospital, Tromsø, Norway, ⁵Department of Rheumatology, University Hospital Lund, Lund, Sweden, ⁶Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ⁷Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark
Background/Purpose: The origin of autoantigens in glomerular immune complex (IC) deposits in lupus nephritis patients is unknown. They may derive from the circulation (microparticle (MP)-ICs…
Abstract Number: 37 • 2013 ACR/ARHP Annual Meeting
Follicular Entry Of Lymphotoxin-Expressing B Cells Via Type I Interferon Disrupts Marginal Zone Barrier Integrity and Exacerbates Systemic Autoimmunity
Hao Li¹, Hui-Chen Hsu², Qi Wu³, Jun Li³, PingAr Yang³, Yang-Xin Fu⁴ and John D. Mountz⁵, ¹Dept. Med - Immunology/Rheumatology division, University of Alabama at Birmingham, Birmingham, AL, ²Birmingham VA Medical Center, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Pathology, The University of Chicago, Chicago, IL, ⁵Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Marginal zone macrophages (MZMs), a small subset of specialized splenic macrophages located in the MZ, act as final follicular entry barrier to clear apoptotic…
Abstract Number: 713 • 2012 ACR/ARHP Annual Meeting
Rpp25 Is a Major Target of Autoantibodies to the Th/to Complex As Measured by ELISA and a New Chemilumiscence Assay
Michael Mahler¹, Cristina Gascon², Sima Patel², Angela Ceribelli³, Edward K.L. Chan³ and Minoru Satoh⁴, ¹Research, INOVA Diagnostics, San Diego, CA, ²Research, INOVA Diagnostics, Inc., San Diego, CA, ³Oral Biology, University of Florida, Gainesville, FL, ⁴Medicine, University of Florida, Gainesville, FL
Background/Purpose: Anti-nuclear antibodies (ANA) play an important role in the diagnosis of systemic autoimmune diseases including systemic sclerosis (SSc). A significant portion of ANA in…
Abstract Number: 2577 • 2012 ACR/ARHP Annual Meeting
Characterization of Circulating Human B Cells That Bind Cyclic Citrullinated Peptide Antigens in Clinically Active Rheumatoid Arthritis
Gregg J. Silverman¹, John Jung², Jeffrey D. Greenberg³, Adam J. Pelzek⁴, Caroline Gronwall⁵ and Jaya Vas⁵, ¹Medical and Pathology, NYU School of Medicine, New York, NY, ²School of Medicine, NYU, New York, NY, ³New York Hospital for Joint Disease, New York, NY, ⁴School of Medicine, NYU School of Medicine, New York, NY, ⁵Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) were first identified based on their high specificity for RA and now are commonly used as a diagnostic tool. Yet,…
Abstract Number: 1391 • 2012 ACR/ARHP Annual Meeting
Anti-Ku Autoantibodies in Systemic Lupus Erythematosus Versus Autoimmune Myositis As Measured by a Novel Chemiluminescence Assay
Michael Mahler¹, Jason Wu², Magdalena Szmyrka-Kaczmarek³, Andreas Swart⁴, Marvin J. Fritzler⁵, Jean-Luc Senécal⁶ and John G. Hanly⁷, ¹Research, INOVA Diagnostics, San Diego, CA, ²Research, INOVA Diagnostics, San Diego, ³Rheumatology, Wroclaw Medical University, Wroclaw, Poland, ⁴Rheumatology clinic Neuss, Neuss, Germany, ⁵Medicine, University of Calgary, Calgary, AB, Canada, ⁶Rheumatology, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ⁷Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada
Background/Purpose: Autoantibodies targeting Ku, an abundant nuclear protein with DNA helicase activity, have been reported in patients with systemic autoimmune rheumatic diseases. Little is known…
Abstract Number: 1081 • 2012 ACR/ARHP Annual Meeting
Toll-Like Receptor 7, 8 and 9 Activation of Primary Human Cells by Lupus Immune Complexes Is Dependent On Interleukin 1 Receptor Associated Kinase 4 Activity
Aaron Winkler¹, Weiyong Sun¹, Ken Dower², Elizabeth A. Murphy¹, Julia Shin¹, Michael Luong¹, Michael J. Primiano¹, Varenka A. Rodriguez², Tatyana Souza¹, Lih-Ling Lin³, J. Perry Hall¹, Katherine Lee⁴, Vikram R. Rao¹ and Margaret Fleming¹, ¹Inflammation & Remodeling, Pfizer, Cambridge, MA, ²Inflammation and Remodeling, Pfizer, Cambridge, MA, ³Inflammation and Remodeling Research Unit, Pfizer, Cambridge, MA, ⁴Worldwide Medicinal Chemistry, Pfizer, Cambridge, MA
Background/Purpose: Genetic, in vitro and in vivo evidence strongly implicate the activation of nucleic acid sensing toll like receptors (TLR) 7, 8, and 9 in…
Abstract Number: 889 • 2012 ACR/ARHP Annual Meeting
Modeling Environmental and Genetic Determinants to Identify the Association of Risk Genes in Anti-Ro60-Mediated Injury: Relaxin Receptor I and Tumor Necrosis Factor
Joanne H. Reed¹, Paula S. Ramos², Jiri Zavadil³, Jill P. Buyon⁴ and Robert M. Clancy¹, ¹Medicine, New York University School of Medicine, New York, NY, ²Department of Medicine, Medical University of South Carolina, Charleston, SC, ³Pathology and Center for Health Informatics and Bioinformtics, New York University School of Medicine, New York, NY, ⁴Department of Medicine, New York University School of Medicine, New York, NY
Background/Purpose: Fetuses exposed to maternal anti-Ro60 antibodies can develop cardiac conduction abnormalities and life threatening cardiomyopathy; manifestations of neonatal lupus (NL). Recent data support an injury…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].